A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy



Status:Completed
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 75
Updated:7/12/2018
Start Date:October 2008
End Date:December 2010

Use our guide to learn which trials are right for you!

Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology
(ACR)50 response scale at 24 weeks


Inclusion Criteria:

- Have given written informed consent

- Women must not be at risk to become pregnant during study participation

- Diagnosis of Rheumatoid Arthritis (RA)

- Current, regular use of Methotrexate, at a stable dose

- Other criteria to be reviewed by study doctor

Exclusion Criteria:

- Use of excluded medications(reviewed by study doctor)

- Have not failed biologic tumor necrosis factor-alpha (TNF-α) inhibitor therapy

- Have had recent or ongoing infection which, in the opinion of the study doctor put
patient at an unacceptable risk for participation in the study

- Evidence of tuberculosis

- Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's
disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy

- Other criteria to be reviewed by study doctor
We found this trial at
7
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
?
mi
from
Calabasas, CA
Click here to add this to my saved trials
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Upland, CA
Click here to add this to my saved trials
?
mi
from
Vero Beach, FL
Click here to add this to my saved trials